|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Alternate Title Phase I/II Study of Obatoclax Mesylate and Topotecan Hydrochloride in Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
Trial Description Obatoclax mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving obatoclax mesylate together with topotecan may help kill more tumor cells. This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan and to see how well they work in treating patients with relapsed or refractory small cell lung cancer or advanced solid tumors. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will receive a 3-hour infusion of obatoclax mesylate on day 1 or days 1 and 3. They will also receive an infusion of topotecan on days 1-5. Treatment may repeat every 3 weeks for as long as benefit is shown. Some patients will undergo tumor tissue sample collection at the beginning of the study for laboratory studies. After finishing treatment, patients will be evaluated for 6 weeks. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Memorial Sloan-Kettering Cancer Center
|
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |